Cipla moves Delhi HC challenging revised price of its formulations
Delhi HC issues notice to National Pharmaceutical Pricing Authority and seeks its response by the next date of hearing
New Delhi: Cipla Ltd moved the Delhi high court on Friday seeking quashing of a notification issued by the National Pharmaceutical Pricing Authority (NPPA) under which the ceiling price of three of its formulations had been revised.
Justice Sanjeev Sachdeva, before whom the matter was brought, issued notice to the pricing authority and sought its response by the next date of hearing.
The pharmaceutical company is challenging a 1 April notification, under which the ceiling prices of its three formulations was revised by NPPA as per the wholesale price index (WPI) without calculating and fixing the ceiling price of such formulations in the first place.
“The ceiling price is fixed for a specified formulation having a specific strength and dosage. There is a huge price difference according to the revised price under the impugned notification," senior advocate Harish Salve, appearing for Cipla, told the court.
The court questioned NPPA on whether such inclusion had happened by mistake or by design. To this, NPPA’s counsel, Sanjeev Narula submitted that the authority had applied its mind and had not taken the decision erroneously.
The case will be heard next on 19 May.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!